尽管Q3收入激增, Trans Medics的库存猛跌52%,令人对未来增长产生疑问。 TransMedics' stock plunges 52% despite Q3 revenue surge, raising questions about future growth.

尽管第三季度收入增长了64%,达到1.08亿美元,但由于销售和利增长低于预期,TransMedics的股价下跌了52%. Despite a 64% revenue increase to $108.8 million in Q3, TransMedics' stock has fallen 52% due to lower-than-expected sales and earnings growth. 该公司的器官护理系统,经林业发展局批准用于器官运输,已获得医院的依赖。 The company's Organ Care System, which is FDA-approved for organ transport, has gained hospital reliance. 2025年,随着持续增长的计划和对临床证据的重视,股票下跌可能为高风险投资者提供购买机会。 With plans for continued growth and a focus on clinical evidence in 2025, the stock dip may offer a purchasing opportunity for high-risk investors.